Clinical trials: Bird Flu
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in children.
- Trial name
- NCT01776554
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 12 sites in United States, Thailand
- Volunteers
- 662 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Avian
Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents
The purpose of this study is to assess the safety and immunogenicity (i.e. primary immune response, immunogenicity of two different doses, antibody persistence 360 days after the first vaccination, immune response to a…
- Trial name
- NCT01052402
- Testing
- H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
- Where
- 20 sites in Australia, Finland and 2 more
- Volunteers
- 684 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children
The objective of the study is to evaluate the immunogenicity and safety of prime-boost vaccination schedule of GSK Biologicals' investigational vaccine GSK1562902A.
- Trial name
- NCT01323946
- Testing
- GSK Biologicals' investigational vaccine GSK1562902A
- Where
- 6 sites in Australia, Singapore
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pandemic Influenza
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza
This aim of this project is to evaluate the efficacy of neuraminidase inhibitors in patients who have a clinical diagnosis of pandemic influenza infection. The study is observational only.
- Trial name
- PIPET A (NCT00640302)
- Where
- 8 sites in Australia
- Sponsor
- Kirby Institute
Influenza, Avian Influenza
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths…
- Conditions
- Influenza, Avian Influenza, Severe Influenza
- Trial name
- NCT00298233
- Testing
- Oseltamivir
- Where
- 12 sites in Singapore, Thailand and 1 more
- Volunteers
- 326 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children
A single center, stratified, randomized and double-blind phase II clinical trial was conducted in children to evaluate the safety and immunogenicity of an split-virion pandemic influenza A vaccine (H5N1).
- Trial name
- NCT00900991
- Testing
- split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Open-Label Study of H5 Vaccine in Participants of Protocol 04-077
This study may provide safety information on a flu vaccine given to children and may provide immunogenicity information to add to what was collected in a previous flu vaccine study.
- Trial name
- NCT00402649
- Testing
- Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
- Where
- 3 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine
This study is a pediatric dose-ranging study to evaluate the safety and immunogenicity of vaccination with different MF59-adjuvanted H5N1 vaccine formulations.
- Trial name
- NCT04669691
- Testing
- H5N1 antigen combined with MF59 adjuvant
- Where
- 7 sites in Estonia, Philippines
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Japanese Pediatric H5N1 Vaccine Study
The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese pediatric population aged 6 months to 17 years
- Trial name
- NCT01911754
- Testing
- H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)
- Where
- 2 sites in Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Pandemic Influenza
A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza
This aim of this project is to evaluate the efficacy of neuraminidase inhibitors as short-term prophylaxis against pandemic influenza infection in people who have close familial contact with the disease.
- Trial name
- PIPET C (NCT00640874)
- Where
- 8 sites in Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kirby Institute
H7N9 Influenza
A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine
The aim of this study is to investigate the immunogenicity and safety of the inactivated whole-virion vaccine for teenagers and adults.
- Trial name
- NCT03369808
- Testing
- 7.5μg H7N9 Vaccine, Phosphate Buffer Solution, Aluminum Hydroxide Adjuvant
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Influenza
A Retrospective, Observational Registry of Participants With Avian Influenza Infection
This is a global, multi-center, observational registry of participants with suspected or confirmed infection with avian influenza A H5N1.
- Trial name
- NCT02743676
- Volunteers
- 648 people
- Sponsor
- Hoffmann-La Roche
Influenza
A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' influenza vaccine in children aged 3 to 17 years.
- Trial name
- NCT01379937
- Testing
- Influenza vaccine GSK1562902A Formulation 1, Influenza vaccine GSK1562902A Formulation 2, Havrix™
- Where
- 2 sites in Philippines
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Phase I Clinical Trial With Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults
Influenza is an acute respiratory infection caused by influenza virus with high incidence and serious complications even causing death.
- Trial name
- NCT01676675
- Testing
- 7.5μg /0.5ml, 15.0μg /0.5ml, 30.0μg /0.5ml
- Where
- China
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza A Virus/H5N1 Subtype
Host Genetic Susceptibility to Avian Influenza A/H5N1
The identification and characterization of susceptibility loci for H5N1 infection in humans could have profound implications. The detection of host genetic factors may shed light on key pathogenic interactions between H5N1 and…
- Trial name
- NCT01074736
- Where
- Vietnam
- Volunteers
- 500 people
- Sponsor
- South East Asia Infectious Disease Clinical Research Network
Influenza
A/H5N1 Vaccine in Healthy Children Aged 2-9 Years
The purposes of this study are: to make sure that there are no serious side effects of an experimental inactivated influenza A/H5N1 vaccine in children; and to see how the body's immune system reacts to the vaccine.
- Trial name
- NCT00133536
- Testing
- Influenza A/H5N1 Vaccine
- Where
- 4 sites in United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
H7N9 Subtype of Influenza A Virus
Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection
The purpose of this program is to provide pre-approval access to pimodivir for the treatment of a patient(s) with H7N9 influenza A infection.
- Trial name
- NCT03834376
- Testing
- Pimodivir
- Sponsor
- Janssen Research & Development, LLC
Influenza
A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age
The purpose of this study is to assess the safety and immunogenicity of different formulations of GSK Biologicals' influenza candidate vaccine GSK1557484A, in children 6-35 months of age.
- Trial name
- NCT02719743
- Testing
- Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
- Where
- 7 sites in Taiwan, Thailand
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Orthomyxoviridae Infections
Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children
This study is part of an effort to develop an effective vaccination program in children in the event of a pandemic. Study objectives: To describe the safety profiles in the periods following each vaccination in subjects receiving…
- Conditions
- Influenza, Orthomyxoviridae Infections, Orthomyxovirus Infections
- Trial name
- NCT00884182
- Testing
- A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine
- Where
- 13 sites in Finland
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age
Currently, there is no standard treatment for influenza with related lower respiratory tract infection (LRTI) in children younger than one year of age, even though influenza related LRTI is a potentially fatal illness in these…
- Trial name
- NCT01037634
- Testing
- Oseltamivir
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)